Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Camoteskimab in Subjects With Adult Onset Still's Disease

Next Previous
Trial Profile

A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Camoteskimab in Subjects With Adult Onset Still's Disease

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camoteskimab (Primary)
  • Indications Adult-onset Still's disease; Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Avalo Therapeutics

Most Recent Events

  • 22 Aug 2023 Status changed from recruiting to discontinued.
  • 14 Mar 2023 Planned number of patients changed from 12 to 20.
  • 14 Mar 2023 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top